RxDoctor Payments Data

Gautam Kareti, MD

Neurology · Lancaster, CANPI 1134326697

Payments from drug & device makers

$306,761in general payments, 2019–2025

Across 405 payments — averaging $757.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$147K
  • Merz Pharmaceuticals, LLC$64K
  • E.r. Squibb & Sons, L.L.C.$46K
  • Novartis$32K
  • AbbVie$9K
  • Biogen$2K
  • plus $6K from 47 others

What the payments were for

  • Travel & lodging$8299%
  • Food & beverage$8,63990%
  • Education$1201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$306,761 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$315,503
Medicare patients
576
Services billed
2,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5017$305,891
Kesimpta PenOfatumumab25$225,021
VumerityDiroximel Fumarate19$200,839
Aimovig AutoinjectorErenumab-Aooe29$24,701
UbrelvyUbrogepant24$23,539
GlatopaGlatiramer Acetate11$22,171
Oxtellar XrOxcarbazepine24$17,737
Lacosamide32$7,850
Levetiracetam259$6,700
Entacapone35$6,403
Carbidopa-Levodopa ErCarbidopa/Levodopa55$5,487
Tiagabine Hcl11$3,423
Pyridostigmine Bromide14$2,480
Carbidopa-LevodopaCarbidopa/Levodopa86$2,356
Memantine Hcl129$2,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam$19$305,89117 claims
BiogenVumerity$1,575$200,83919 claims
AbbVieUbrelvy$9,448$23,53924 claims
SandozGlatopa$19$22,17111 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$19$17,73724 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$143$2,48014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in Lancaster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →